Previous 10 | Next 10 |
2023-10-18 03:30:00 ET Summary ClearBridge All Cap Value Strategy invests in a diversified portfolio of stocks whose prices are undervalued in relation to underlying fundamentals. The transition to a higher rate environment has increased risks and concerns over companies accustome...
2023-10-17 07:30:08 ET More on Gamida Cell Gamida Cell: The Treacherous Path To Profitability Gamida Cell Ltd. (GMDA) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Gamida Cell Historical earnings data for Gamida Cell Financia...
2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...
2023-10-08 09:40:00 ET Summary Jiangsu QYuns Therapeutics has filed for a Hong Kong IPO to underwrite development of its portfolio of clinical-stage biologic antibody drugs for autoimmune and allergic diseases. Taiwan’s PharmaEssentia has acquired a myeloid immune checkpoin...
2023-10-04 03:04:43 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-10-03 13:53:21 ET More on ProMIS Neurosciences ProMIS Neurosciences scales 31% on $20.4M private placement ProMIS stock rockets 115% amid preclinical data for Alzheimer's drug Historical earnings data for ProMIS Neurosciences Financial information for Pr...
2023-09-29 16:46:22 ET Summary Biogen's stock has increased by over 30% since the release of my bullish note on the company in June 2022, primarily driven by the approval of its Alzheimer's drug, Leqembi. Leqembi is now fully approved and eligible for reimbursement - peak sales co...
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWS...
2023-09-26 17:17:11 ET Biogen Inc. (BIIB) Decentralized Clinical Trials in Focus Conference September 26, 2023, 10:00 AM ET Company Participants Stephanie Manson Brown - Head of Clinical Development and Scientific Innovation & VP at R&D Allergan Aesthetics, AbbVi...
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...